BAYER Schering has signed a
deal with EndoCeutics for the
development and commercialisation
of a new intra-vaginal medication
for the treatment of vaginal atrophy
and female sexual dysfunction in
postmenopausal women.
According to Bayer, Vaginorm
(dehydroepiandrosterone or DHEA),
which is currently in its phase III
trials, is set to meet a “largely
unmet medical need” in treating
women who experience changes to
their vaginal tissue after
menopause, with reports showing
almost 25% of all post menopausal
women suffer from one form or
another of vaginal atrophy.The above article was sent to subscribers in Pharmacy Daily's issue from 06 May 10 To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 06 May 10
MONTU Group, its subsidiary Alternaleaf Pty Ltd, and their common director Christopher Strauch are facing legal action by the Therapeutic Goods Administration (TGA) in the Federal Court of Australia for alleged unlawful advertising on the effectiveness of their medicinal cannabis products.
FREE Pharmacy Daily subscription - never miss another story!
to top
Subscribe to Pharmacy Daily
Pharmacy Daily subscription confirmation
Thank you for signing up! Check your email inbox – you should shortly receive a message with a link which must be clicked to confirm your subscription.
Once you’ve done that you will begin receiving Pharmacy Daily as soon as the next issue is published.